Antiangiogenic VEGF-Ax: A New Participant in Tumor Angiogenesis

Eswarappa, Sandeepa M and Fox, Paul L (2015) Antiangiogenic VEGF-Ax: A New Participant in Tumor Angiogenesis. In: CANCER RESEARCH, 75 (14). pp. 2765-2769.

PDF Can_Res_75-14_2765_2015.pdf - Published Version Restricted to Registered users only Download (521kB) | Request a copy

Abstract

The transcript of the angiogenic factor vascular endothelial growth factor A (VEGF-A) is subject to a multitude of stimulus-dependent, posttranscriptional regulatory events, consistent with its unusually long 30 untranslated region. We have recently reported translational readthrough of VEGFA mRNA whereby translating ribosomes traverse the canonical stop codon to a conserved, downstream stop codon, generating VEGF-Ax (''x'' for extended), a novel, extended isoform with an additional 22 amino acids appended at the C-terminus. This event is the first vertebrate example of protein-regulated, programmed translational readthrough that generates a protein with a known function. Remarkably, VEGF-Ax exhibits potent antiangiogenic activity, both in vitro and in vivo, thus raising profound clinical implications, particularly with respect to cancer treatment. In this review, we discuss the potential of VEGF-Ax as a therapeutic agent and drug target, as well as its possible role in the failure of, or resistance to, conventional anti-VEGF therapies in many types of cancers. (C) 2015 AACR.

Item Type:	Journal Article
Publication:	CANCER RESEARCH
Publisher:	AMER ASSOC CANCER RESEARCH
Additional Information:	Copy right for this article belongs to the AMER ASSOC CANCER RESEARCH, 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
Department/Centre:	Division of Biological Sciences > Biochemistry
Date Deposited:	03 Sep 2015 06:17
Last Modified:	03 Sep 2015 06:17
URI:	http://eprints.iisc.ac.in/id/eprint/52295

Actions (login required)

View Item